At Mallinckrodt, we believe our corporate responsibility goes beyond the millions of people whose lives we touch each and every day.
We’ve integrated responsible business practices into everything we do. From our broad efforts to encourage responsible and safe use of opioid pain medications to advocating for patient health and access to medicines, our commitment to building a better tomorrow is stronger than ever.
Explore how Mallinckrodt is committed to conducting responsible business for a healthier world.
A core pillar of our corporate responsibility is giving back to the communities that have helped us grow for more than 150 years. We partner with organizations that are making a tangible difference and driving positive change within local communities through education, economic development and cultural enrichment.
Mallinckrodt is committed to establishing and maintaining an effective Compliance Program in accordance with the applicable laws, regulations, and Codes of the countries within which it operates. Our global Compliance Program is one of the key components of our commitment to the highest standards of corporate conduct.
At Mallinckrodt, transparency is an essential part of building and preserving the trust of our employees, shareholders, and the patients and families we serve. We are pleased to issue our first annual Corporate Social Responsibility (CSR) report – an expansion of our 2018 Political Transparency Report – that illustrates our wide-ranging commitment to corporate stewardship. The report highlights Mallinckrodt’s CSR priorities and ongoing initiatives, including our innovative pipeline and commitment to patients, responsible business practices that promote the highest standards of ethics and transparency, and unwavering dedication to being a good employer, neighbor and corporate citizen.
It is Mallinckrodt’s policy to be able to provide appropriate and ethical access to its investigational medicines to patients under certain defined circumstances prior to marketing authorization, but outside of the planned clinical research program. Such Expanded Access Programs (often called “Compassionate Use” programs), are for exceptional circumstances only.
Learn more about our expanded access program for investigational products
Mallinckrodt has a long-standing policy of abiding by industry ethical codes on its interaction with healthcare professionals.
Learn more about our commitment
Mallinckrodt’s Pledge to America: Create the best possible healthcare at the lowest possible cost for the greatest number of people.
Read our pledge on drug pricing and innovation
At Mallinckrodt, we believe our commitment to quality, health, safety and our environment starts with a socially responsible culture. That’s why we remain focused on building quality, safety and environmental excellence into all of our processes from start to finish.
Mallinckrodt is dedicated to providing safe and effective medications for the treatment of patients with pain and is equally committed to working with policymakers, law enforcement, patient groups and other stakeholders to address the complex issues of opioid diversion and abuse.
Sustainability has always been an important part of our heritage, and it will continue to be as we evolve and progress toward the future.